Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
Carl J. Baldick(Bristol-Myers Squibb (United States)), Richard J. Colonno(Assembly Biosciences (United States)), Steven M. LeVine(Kaiser Permanente Oakland Medical Center), Ronald E. Rose(Bristol-Myers Squibb (United States)), Betsy J. Eggers(Bristol-Myers Squibb (United States)), Kevin A. Pokornowski(Bristol-Myers Squibb (United States)), Cheng-Fang Yu(Bristol-Myers Squibb (United States)), Jie Fang(Chinese Academy of Sciences), Daniel J. Tenney(Bristol-Myers Squibb (Germany))
Cited by 68
Related Papers
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
|Gastroenterology|2006|414
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239